NUVL
Price
$103.77
Change
-$3.40 (-3.17%)
Updated
Feb 4, 03:04 PM (EDT)
Capitalization
8.32B
28 days until earnings call
Intraday BUY SELL Signals
RLAY
Price
$8.36
Change
-$0.32 (-3.69%)
Updated
Feb 4, 03:15 PM (EDT)
Capitalization
1.5B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs RLAY

Header iconNUVL vs RLAY Comparison
Open Charts NUVL vs RLAYBanner chart's image
Nuvalent
Price$103.77
Change-$3.40 (-3.17%)
Volume$3.1K
Capitalization8.32B
Relay Therapeutics
Price$8.36
Change-$0.32 (-3.69%)
Volume$1.3K
Capitalization1.5B
NUVL vs RLAY Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. RLAY commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Buy and RLAY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (NUVL: $107.17 vs. RLAY: $8.67)
Brand notoriety: NUVL and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 66% vs. RLAY: 263%
Market capitalization -- NUVL: $8.32B vs. RLAY: $1.5B
NUVL [@Biotechnology] is valued at $8.32B. RLAY’s [@Biotechnology] market capitalization is $1.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, both NUVL and RLAY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 6 TA indicator(s) are bullish while RLAY’s TA Score has 5 bullish TA indicator(s).

  • NUVL’s TA Score: 6 bullish, 3 bearish.
  • RLAY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than RLAY.

Price Growth

NUVL (@Biotechnology) experienced а +0.68% price change this week, while RLAY (@Biotechnology) price change was +2.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

RLAY is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($8.32B) has a higher market cap than RLAY($1.5B). NUVL YTD gains are higher at: 6.541 vs. RLAY (2.482). RLAY has higher annual earnings (EBITDA): -322.8M vs. NUVL (-398.38M). NUVL has more cash in the bank: 943M vs. RLAY (596M). RLAY has higher revenues than NUVL: RLAY (8.36M) vs NUVL (0).
NUVLRLAYNUVL / RLAY
Capitalization8.32B1.5B554%
EBITDA-398.38M-322.8M123%
Gain YTD6.5412.482264%
P/E RatioN/AN/A-
Revenue08.36M-
Total Cash943M596M158%
Total DebtN/A33.3M-
TECHNICAL ANALYSIS
Technical Analysis
NUVLRLAY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 20 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
FOREX / NAMEPrice $Chg $Chg %
AUDCAD0.95N/A
N/A
Australian Dollar - Canadian Dollar
GBPNZD2.27N/A
N/A
United Kingdom Pound - New Zealand Dollar
NZDAUD0.86N/A
N/A
New Zealand Dollar - Australian Dollar
CHFGBP0.94N/A
N/A
Switzerland Franc - United Kingdom Pound
QDTE30.52-0.45
-1.45%
Roundhill Innovt-100 0DTE CovCllStratETF

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.12%
XNCR - NUVL
61%
Loosely correlated
-0.99%
CGON - NUVL
60%
Loosely correlated
-3.28%
RVMD - NUVL
59%
Loosely correlated
-1.22%
IDYA - NUVL
58%
Loosely correlated
+0.50%
XENE - NUVL
58%
Loosely correlated
+1.62%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with BDTX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
+6.38%
BDTX - RLAY
55%
Loosely correlated
-0.79%
NRIX - RLAY
55%
Loosely correlated
-1.76%
IMNM - RLAY
52%
Loosely correlated
+3.18%
IMTX - RLAY
50%
Loosely correlated
-0.40%
NUVL - RLAY
50%
Loosely correlated
+2.12%
More